<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002263</url>
  </required_header>
  <id_info>
    <org_study_id>067B</org_study_id>
    <secondary_id>206</secondary_id>
    <nct_id>NCT00002263</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine</brief_title>
  <official_title>A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To assess the safety and efficacy of subcutaneous sargramostim ( granulocyte-macrophage&#xD;
      colony-stimulating factor; GM-CSF ) in increasing and maintaining the granulocyte count in&#xD;
      HIV-infected children who have developed granulocytopenia as a result of continuous&#xD;
      intravenous ( CIV ) zidovudine ( AZT ). To assess the short-term and long-term effects of&#xD;
      concomitant GM-CSF on other hematologic parameters. To assess the potential therapeutic&#xD;
      benefit of concomitant GM-CSF and AZT on the natural history of HIV infection and associated&#xD;
      infectious complications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <condition>Cytopenias</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Zidovudine (AZT) on NIAID 86-C-175.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Diagnosis of perinatal or transfusion acquired AIDS or AIDS related complex.&#xD;
&#xD;
          -  Granulocytopenia (&lt; or = to 800 cells/mm3) associated with the administration of AZT&#xD;
             on protocol NIAID 86-C-175.&#xD;
&#xD;
          -  Life expectancy &gt; 3 months.&#xD;
&#xD;
          -  Functioning indwelling central venous access device in place.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed within 48 hours of study entry:&#xD;
&#xD;
          -  Prophylactic antibiotics.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Critically ill or clinically unstable.&#xD;
&#xD;
          -  Significant, active opportunistic or other infection requiring specific drug therapy&#xD;
             at time of study entry.&#xD;
&#xD;
          -  Ongoing IV alimentation.&#xD;
&#xD;
          -  Uncorrected nutritional deficiencies that may contribute to anemia and/or leukopenia.&#xD;
&#xD;
          -  Past history of or current evidence for any chronic hematologic disorder other than&#xD;
             hemophilia A or B, anemia of chronic disease or anemia related to HIV infection.&#xD;
&#xD;
          -  Malignancy likely to require systemic treatment during study.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Critically ill, clinically unstable, or with concomitant diseases listed in Patient&#xD;
             Exclusion Co-existing Conditions.&#xD;
&#xD;
          -  Hypersensitivity to zidovudine (AZT) or any other nucleoside analog.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 48 hours of study entry:&#xD;
&#xD;
          -  Antibiotics.&#xD;
&#xD;
          -  Excluded within 30 days of study entry:&#xD;
&#xD;
          -  Antiretroviral agents other than zidovudine (AZT).&#xD;
&#xD;
          -  Acyclovir.&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  Any investigational drug.&#xD;
&#xD;
          -  Immunomodulating drugs.&#xD;
&#xD;
          -  Cytolytic chemotherapeutic agents.&#xD;
&#xD;
          -  Corticosteroids.&#xD;
&#xD;
          -  Immunoglobulin preparations.&#xD;
&#xD;
          -  Excluded within 4 months of study entry:&#xD;
&#xD;
          -  Suramin.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 6 months of study entry:&#xD;
&#xD;
          -  Bone marrow transplantation.&#xD;
&#xD;
          -  Excluded within 4 weeks of study entry:&#xD;
&#xD;
          -  Lymphocyte transfusions.&#xD;
&#xD;
          -  Radiation therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Natl Cancer Institute / HIV / AIDS Malignancy Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 1990</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Pilot Projects</keyword>
  <keyword>Neutropenia</keyword>
  <keyword>Granulocyte-Macrophage Colony-Stimulating Factor</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

